


Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 3

Please replace the existing Abstract of the Disclosure with the following:

ABSTRACT OF THE DISCLOSURE

Disclosed are novel adenosine A₃ receptor agonists of Formula I:



Formula I

wherein:

R is hydrogen or lower alkyl;

R¹ is optionally substituted lower alkoxy or optionally substituted cycloalkyloxy;

R² is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl, or optionally
substituted trialkylsilyl; and

R³ is hydroxymethyl or R⁴R⁵NC(O)-;

in which R⁴ and R⁵ are hydrogen, optionally substituted alkyl, optionally substituted
cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally
substituted heteroaryl.